Results 11 to 20 of about 38,820 (264)
Automated GMP compliant production of [18F]AlF-NOTA-octreotide
EJNMMI Radiopharmacy and Chemistry, 2020 Background Gallium-68 labeled synthetic somatostatin analogs for PET/CT imaging are the current gold standard for somatostatin receptor imaging in neuroendocrine tumor patients.
Térence Tshibangu +7 more
doaj +2 more sources
Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2019 Objective(s): In view of somatostatin receptor (SSR) expression on cell membranes of the majority of neuroendocrine tumors (NETs), functional imaging exploiting analogs of SSR alongside the anatomical imaging is the mainstay of this diagnostic modality ...
Babak Fallahi +8 more
doaj +2 more sources
Expert Opinion on Drug Delivery, 2021 Introduction The FDA approval of oral semaglutide for type 2 diabetes (2019) and oral octreotide for acromegaly (2020) is evidence that selected niche peptides can be administered orally if formulated with selected intestinal permeation enhancers.
David J Brayden, S. Maher
semanticscholar +1 more source
Clinical Cancer Research, 2020 Purpose: Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas.
T. Graillon +21 more
semanticscholar +1 more source
Scientific Reports, 2023 Octreotide, a somatostatin analogue, has shown its efficacy for the diagnostics and treatment of various types of cancer, i.e., in octreotide scan, as radio-marker after labelling with a radiopharmaceutical.
Jonas Lins +10 more
doaj +1 more source
Octreotide and hepatocellular carcinoma [PDF]
British Journal of Cancer, 2007 Sir, The treatment of advanced hepatocellular carcinoma (HCC) in patients no longer eligible for surgical, percutaneous or transarterial therapies is dismal. Chemotherapy, anti-estrogens or anti-androgens, retinol derivatives or stem cell factors have been tested with poor results, and we eagerly wait for the results of ‘biologic' treatments, such ...
F. Farinati +4 more
openaire +3 more sources
Journal of Medical Case Reports, 2011 Introduction The safety of octreotide use, in its short-acting preparation, in pregnancy is still unclear. This report provides the first documentation of uneventful octreotide LAR use during three pregnancies in a woman with bronchial carcinoid ...
Naccache Deeb +5 more
doaj +1 more source
Current diagnosis and treatment of acute pancreatitis in China: a real-world, multicenter study
BMC Gastroenterology, 2021 Background Efficacy of pancreatic enzyme inhibitors in acute pancreatitis (AP) is unclear in China. Aims We aimed to present the current status of AP and evaluate the efficacy of pancreatic enzyme inhibitors in a larger population in China.
Chuandong Sun +3 more
doaj +1 more source
Therapeutic applications of octreotide in pediatric patients
The Saudi Journal of Gastroenterology, 2012 Background/Aim: We report our experience with the use of octreotide as primary or adjunctive therapy in children with various gastrointestinal disorders.
Abdulrahman Al-Hussaini, Decker Butzner
doaj +1 more source
World Journal of Gastroenterology, 2015 AIM To review literature on efficacy and safety of octreotide-long-acting repeatable (LAR) used at doses higher than the Food and Drug Administration (FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors (NETs).
M. Broder +4 more
semanticscholar +1 more source